Variable response to oral angiotensin-converting-enzyme blockade in hypertensive scleroderma patients.
Twelve scleroderma patients with hypertension, seven of whom had malignant hypertension and renal failure of scleroderma renal crisis, were treated with captopril. The first dose lowered mean pressure in all patients by 21.3 mmHg; in 6 patients it relieved encephalopathy. Blood pressure was controlled in all patients. Two of 7 patients with scleroderma renal crisis had improvement in renal function; the 5 patients who did not have malignant hypertension improved or stabilized. Despite good pressure control, however, renal failure developed in 5 patients with scleroderma renal crisis. The data indicated that captopril is effective antihypertensive therapy in scleroderma and, when given early, may prevent renal failure and death.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors; D002216:Captopril / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D006974:Hypertension, Malignant / Q000188:drug therapy; D008875:Middle Aged; D012083:Renin / Q000097:blood; D012595:Scleroderma, Systemic / Q000150:complications / Q000188:drug therapy* / Q000401:mortality
D000806:Angiotensin-Converting Enzyme Inhibitors; D002216:Captopril; D003404:Creatinine; D012083:Renin